الفهرس 
Reviews of literatureOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
It was decided globally and it was found that at the top of all health problems colorectal cancer diseases and it were became the third most common cancer worldwide after lung and breast cancers with two-thirds of all colorectal cancers occurring in the developed regions of the world. In Egypt, CRC represents only 3% of all malignant tumors Therefore, the correct and early diagnosis of colorectal cancer helps greatly in the healing and purity of it by the use of diagnostic tools including the detection of the presence of its specific tumor markers, which is useful quickly to ensure the presence of disease or not.
In this study, we investigated and confirmed two markers of colorectal cancer which are CEA and TIMP-1 in addition; we performed screening for single-nucleotide polymorphism (SNP) in Egyptian patients and studied them for the presence of SNP in the genes and the association of the disease by it.
the current results specified that there is a significant variations in the grade of concentration of CEA and TIMP-1 markers among the studied groups of control group and patients group with a clear appearance for a significant rising in patients . and therefore we make sure that these markers are associated with the disease .
We investigated in this study the relationship of single nucleotide polymorphisms (SNPs) at exon 13 (P757L) of the exonuclease -1 (EXO - 1) gene with development, progression and metastasis of colorectal cancer in Egyptian patients and we found that people with the Leu/Leu (wild-type) genotype showed a reduced risk of colorectal cancer compared with pro/leu and pro/pro genotypes.
In conclusion:-
Currently, we can recommended and verify the use of both CEA and TIMP-1 markers in early diagnosis of CRC and we also can detect the presence of SNPs and the association of the gene P757L genotyping that can alter or increase the risk of the presence of the colorectal cancer.